FDA approves another over-the-counter Naloxone nasal spray

The RiVive over-the-counter naloxone nasal spray. [Image from Harm Reduction Therapeutics]

Harm Reduction Therapeutics announced that it received FDA approval for its over-the-counter RiVive naloxone nasal spray.

Pittsburgh-based HRT designed the 3 mg naloxone HCl nasal spray for the emergency treatment of opioid overdose. Approval helps make free or low-cost OTC nasal spray widely available in the U.S.

The FDA first approved Narcan 4 mg OTC naloxone nasal spray in March of this year. A different opioid overdose therapeutic, the Opvee nalmefene hydrochloride nasal spray from Opiant Pharmaceuticals, received approval in May.

RiVive uses an easy-to-use standard dose unit system. Each nasal spray device contains one dose. HRT plans to offer it exclusively in twin packs containing two single-dose devices.

“We are grateful that FDA granted RiVive approval so we can now achieve what most thought i…

Read more
  • 0